Cost-effectiveness of parenteral artesunate for treating children with severe malaria in sub-Saharan Africa
Yoel Lubell, Arthorn Riewpaiboon, Arjen M Dondorp, Lorenz von Seidlein, Olugbenga A Mokuolu, Margaret Nansumba, Samwel Gesase, Alison Kent, George Mtove, Rasaq Olaosebikan, Wirichada Pan Ngum, Caterina I Fanello, Ilse Hendriksen, Nicholas PJ Day, Nicholas J White & Shunmay Yeung
Volume 89, Number 7, July 2011, 504-512
Table 6. Hospital admissions for severe malaria and impact on hospital budgets of switching from parenteral quinine to artesunate to treat severe malaria in childen
| Paremeter | United Republic of Tanzania |
Mbarara, Uganda | Ilorin, Nigeria | |
|---|---|---|---|---|
| Muheza | Korogwe | |||
| Patients admitted with severe malaria per year (No.) | 555 | 169 | 584 | 708 |
| Annual cost of switching to artesunate including hotel costs (US$)a | 699 | −271 | 526 | 16 142 |
| Annual cost of switching to artesunate excluding hotel costs (US$) b | 755 | −509 | 876 | 3894 |
US$, United States dollar.
a Overhead costs for inpatient care as estimated in the WHO-CHOICE database.
b Only direct expenditure that will be affected by switching from quinine to artesunate.